Page 1 of Clinical Trials for Merrimack Pharmaceuticals [SPONSOR-COLLABORATORS], 19 Total Matches
- 1RecruitingLast Updated: January 31, 2011Condition(s): Advanced Solid Tumors
- 2RecruitingLast Updated: May 14, 2012Condition(s): Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
- 3RecruitingLast Updated: May 18, 2012Condition(s): Metastatic Pancreatic Cancer
- 4RecruitingLast Updated: January 20, 2012Condition(s): Carcinoma, Non-Small-Cell Lung
- 5RecruitingLast Updated: January 20, 2012Condition(s): Solid Tumors
- 6CompletedLast Updated: February 21, 2007Condition(s): Psoriasis
- 7RecruitingLast Updated: January 20, 2012Condition(s): Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
- 8CompletedLast Updated: December 16, 2008Condition(s): Uveitis
- 9CompletedLast Updated: March 24, 2008Condition(s): Rheumatoid Arthritis
- 10RecruitingLast Updated: May 14, 2012Condition(s): Her2 Negative Breast Cancer Patients
- 11RecruitingLast Updated: March 19, 2012Condition(s): HER2 Amplified Breast Cancer; Metastatic or Advanced Breast Cancer
- 12RecruitingLast Updated: April 25, 2012Condition(s): ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
- 13CompletedLast Updated: July 10, 2008Condition(s): Rheumatoid Arthritis
- 14RecruitingLast Updated: March 19, 2012Condition(s): HER-2 Gene Amplification
- 15RecruitingLast Updated: May 1, 2012Condition(s): Advanced Solid Tumors
- 16RecruitingLast Updated: January 31, 2011Condition(s): Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,; Primary Peritoneal Cancer or Endometrial Cancer; Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- 17RecruitingLast Updated: November 17, 2011Condition(s): Breast Cancer
- 18CompletedLast Updated: March 19, 2012Condition(s): Her2 Amplified Solid Tumors; Metastatic Breast Cancer
- 19RecruitingLast Updated: April 30, 2012Condition(s): Solid Tumor Cancers
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?spons=Merrimack+Pharmaceuticals
